Neurocrine Biosciences (NASDAQ:NBIX) Insider Ingrid Delaet Sells 3,401 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 3,401 shares of Neurocrine Biosciences stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $178.57, for a total value of $607,316.57. Following the completion of the sale, the insider directly owned 16,225 shares of the company’s stock, valued at approximately $2,897,298.25. This represents a 17.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet also recently made the following trade(s):

• On Wednesday, July 8th, Ingrid Delaet sold 2,737 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.54, for a total value of $488,663.98.
• On Thursday, July 9th, Ingrid Delaet sold 8,433 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.72, for a total value of $1,507,145.76.
• On Friday, May 29th, Ingrid Delaet sold 2,261 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $156.71, for a total value of $354,321.31.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $180.55 on Friday. The company has a market cap of $18.15 billion, a P/E ratio of 27.82, a P/E/G ratio of 0.71 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $181.00. The company has a 50-day moving average of $159.92 and a 200-day moving average of $142.66.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NBIX. HC Wainwright lifted their price target on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Citigroup increased their target price on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Wedbush lifted their target price on Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Needham & Company LLC reissued a “buy” rating and set a $185.00 price target on shares of Neurocrine Biosciences in a research report on Monday, April 6th. Finally, Guggenheim restated a “buy” rating and set a $175.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $188.10.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: NBIX was upgraded to Zacks Rank #1 (Strong Buy), signaling improved earnings optimism and potentially supporting further upside. Article Title
• Positive Sentiment: News that Neurocrine has started a Phase 2 CAH study in children under 4 may be encouraging for the pipeline, and another article suggested the stock could be undervalued after the new study. Article Title Article Title
• Neutral Sentiment: Neurocrine announced it will host its second-quarter 2026 earnings conference call and webcast on July 30; this is important upcoming catalyst news, but it does not change fundamentals by itself. Article Title
• Neutral Sentiment: A separate note said NBIX looks fair on earnings but pricey versus biotechs, which is more of a valuation check than a clear stock-moving event. Article Title
• Negative Sentiment: Insider Ingrid Delaet sold shares in three transactions over July 7-9. The sales were made under a pre-arranged 10b5-1 plan, which limits how bearish the signal is, but insider selling can still temper enthusiasm. Article Title

Institutional Investors Weigh In On Neurocrine Biosciences

Several institutional investors and hedge funds have recently modified their holdings of NBIX. AQR Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 83.7% during the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after buying an additional 1,263,633 shares during the period. Norges Bank purchased a new position in Neurocrine Biosciences in the 4th quarter worth approximately $162,664,000. UBS Group AG grew its position in Neurocrine Biosciences by 169.8% in the fourth quarter. UBS Group AG now owns 983,528 shares of the company’s stock valued at $139,494,000 after acquiring an additional 618,956 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock worth $126,367,000 after purchasing an additional 472,408 shares in the last quarter. Finally, Zurich Insurance Group Ltd FI acquired a new position in shares of Neurocrine Biosciences during the fourth quarter worth $65,162,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.